m+Medelevator.RU
← Поиск публикаций
NPJ digital medicine · 2026

Deep chemical structure graph learning deciphers the lipotoxicity code of hypertriglyceridemic pancreatitis.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Huang Anliang, Yuan Qihang, Chen Junhong, Wang Lei, Yu Yanlong, Zhang Yunshu, Ma Shurong, Liu Kai, Wu Zeming, Cao Shengji, Liu Tianyi, Shang Dong, Yin Peiyuan

Аннотация

The discrepancy between serum triglyceride levels and the clinical severity of hyperlipidemic acute pancreatitis (HLAP) complicates risk stratification. Traditional lipidomics, which primarily rely on linear abundance, often fail to distinguish the HLAP-specific lipidome from the metabolic background of hypertriglyceridemia (HTG). To overcome this limitation, DeepLipiDecipher was developed as a knowledge-guided graph neural network framework that integrates lipid chemical structures with metabolic topology to identify latent lipotoxic features. In a retrospective cohort of 433 subjects, DeepLipiDecipher demonstrated robust classification performance (AUC = 0.810), effectively distinguishing the HLAP phenotype and outperforming conventional machine learning models. Interpretability analysis revealed that HLAP susceptibility correlated with a distinct structural lipid profile, marked by the synergistic enrichment of polyunsaturated and ether-linked phospholipids, rather than total lipid mass. Moreover, computational causal inference implicated a pathogenic mechanism wherein SMPD3-mediated ceramide accumulation induced basal cytotoxicity, and PTGS2 hyperactivation promoted the peroxidation of these vulnerable lipids, triggering systemic inflammation. These results highlight the value of incorporating network topology into lipidomic analysis and suggest the network-inferred SMPD3-Ceramide-PTGS2 immunometabolic axis as a potential therapeutic target for preventing the progression from metabolic dysfunction to acute organ injury.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты